Ulcerative colitis: Impact of early disease clearance on long-term outcomes - A multicenter cohort study

Data de publicação: Data Ahead of Print:

Autores da FMUP

  • Fernando José Magro Dias

    Autor

Participantes de fora da FMUP

  • D'Amico, Ferdinando
  • Fiorino, Gionata
  • Solitano, Virginia
  • Massarini, Eugenia
  • Guillo, Lucas
  • Allocca, Mariangela
  • Furfaro, Federica
  • Zilli, Alessandra
  • Bonovas, Stefanos
  • Peyrin-Biroulet, Laurent
  • Danese, Silvio

Unidades de investigação

Abstract

Background Clinical remission and endoscopic mucosal healing are the main treatment targets in patients with ulcerative colitis (UC). Recently, the concept of disease clearance has been proposed as a potential target in UC. Objective We aimed to evaluate the impact of disease clearance on long-term outcomes in UC patients. Methods A multicenter retrospective cohort study was conducted at the Humanitas Research Hospital-IRCCS (Italy) and at the Nancy University Hospital (France) between 2014 and 2021. Disease clearance in UC was defined as simultaneous clinical (partial-Mayo score <= 2), endoscopic (endoscopic-Mayo score = 0), and histological (Nancy index = 0) remission, and patients were monitored over a long-time follow-up (>= 12 months), to compare the occurrence of negative outcomes. Results A total of 494 patients with UC was included in the study (269, 54.4% males). Disease clearance was present in 109 patients (22.1%) at baseline. Median follow up was 24 months. Patients with disease clearance were associated to a significantly lower risk of UC-related hospitalization compared with the control group (5.5% vs. 23.1%; p < 0.001) at last observation. Similarly, a lower rate of surgeries was detected in patients with disease clearance at baseline compared with those without (1.8% vs. 10.9%; p = 0.003). The Kaplan Meier curves confirmed that patients with disease clearance at baseline had a lower risk of hospitalization (log-rank p < 0.0001) and surgery (log-rank p < 0.00095). Conclusion In UC patients with early disease clearance are at significant lower risk for hospitalization and surgery. Disease clearance should be considered as a new composite outcome.

Dados da publicação

ISSN/ISSNe:
2050-6406, 2050-6414

United European Gastroenterology Journal  John Wiley &amp; Sons Inc.

Tipo:
Article
Páginas:
775-782
Link para outro recurso:
www.scopus.com

Citações Recebidas na Web of Science: 19

Citações Recebidas na Scopus: 21

Documentos

  • Não há documentos

Métricas

Filiações mostrar / ocultar

Keywords

  • deep remission; disease clearance; inflammatory bowel disease; ulcerative colitis

Proyectos asociados

Gut microbiome and IBD therapy: an interplay?

Investigador Principal: Fernando José Magro Dias

Estudo Observacional Académico (GutIBD) . 2021

Iron deficiency and inflammatory bowel disease. Correlation with inflammation and Vitamin D status.

Investigador Principal: Fernando José Magro Dias

Estudo Observacional Académico (IronIBD) . 2021

Looking 4WARD: The role of dipeptidyl peptidase 4 (DPP-4) in inflammatory bowel disease (IBD) as a novel biomarker for predicting disease activity and monitoring response to therapy in IBD patients.

Investigador Principal: Fernando José Magro Dias

Estudo Observacional Académico (4WARD) . 2021

Isolated Ulceration of Crohn’s Anastomosis

Investigador Principal: Fernando José Magro Dias

Estudo Clínico Académico . 2021

Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy

Investigador Principal: Fernando José Magro Dias

Estudo Clínico Académico . 2022

Therapeutic Drug Monitoring: An Emergent Approach in Inflammatory Bowel Disease

Investigador Principal: Fernando José Magro Dias

Estudo Clínico Académico . 2021

Contributo da endoscopia, biomarcadores e imagiologia na evolução clinica dos doentes com doença inflamatória intestinal

Investigador Principal: Fernando José Magro Dias

Estudo Clínico Académico . 2019

Citar a publicação

Partilhar a publicação